Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
about
KRAS mutational analysis for colorectal cancer. Application: pharmacogenomicAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondPIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerSignaling cross-talk in the resistance to HER family receptor targeted therapyImpact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerDevelopment of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasisUsing genetics and genomics strategies to personalize therapy for cancer: focus on melanomaChromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancerPanitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.New trends in epidermal growth factor receptor-directed monoclonal antibodies.The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met.Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsCombination drug delivery approaches in metastatic breast cancerInsulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic AnalysisPrognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma.c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastasesMolecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.Treatment in advanced colorectal cancer: what, when and how?High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissuePharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.
P2860
Q21128654-268BAA73-D2E9-4F08-82FB-E2CE569491A1Q24563539-790F3378-F286-4475-97F4-DAB8B0C71C31Q26822817-D5653AE0-48E2-4EAF-971D-CE2A080F6E0BQ26992267-22457F4F-136E-43A0-B20F-36FF85E9A631Q27015224-02825DE3-49CD-4763-A6C3-F24A400632D7Q27027648-6D4762F3-1967-4D68-BCA4-02066FBD145DQ27027778-3A968C46-A4A0-4E02-A557-E92D452F50F9Q27851892-D997EC01-A2D4-4E65-8096-B15805161086Q27852970-7112F58F-1771-4A60-B68B-55E296647572Q28076490-5EB2C92D-EE5A-4543-AD82-F25327778C17Q33927952-249519DB-C392-49FA-8216-FD839EA911E7Q33947318-0BD21DB1-58C5-4255-98F2-8C601FA85C72Q33965328-99C82257-5679-410B-9C9D-452C74CF93D3Q34198721-990E5015-03E3-4415-991A-D1D441BDDC2EQ34239801-60C70B3D-192B-472B-B837-9983663A3DDDQ34621577-72CBB1E2-6B16-4D7A-A3EB-48F530B0F667Q34776118-9854EAEC-195B-4036-807D-9E3361338C83Q35051660-83A3E3B5-53B8-487E-80B1-8AF81A8A1349Q35067570-B1A691FC-67E9-4A0C-9E08-188411BFBECAQ35083740-88911053-8CCA-4CEA-AB76-9FFCC3DE421BQ35231369-84416B76-8A94-4B33-88D3-07161EA2B775Q35584153-71D6EC8F-9B75-41D6-9696-BFAC155ABDA6Q35713396-6D68D46A-CCFF-48EB-BECC-A9B5E2B5937DQ35926926-961E95D3-4CE1-4527-A9AF-FAFAA731CA95Q35955198-A17BCE04-46C7-4A94-BE51-67F18838D6E0Q35994860-7F35062E-D39F-43F7-841D-1688716C4562Q36039967-AE7DE194-1F96-452D-9468-4F34B007C432Q36115580-DC7C5403-23CE-4ADA-851A-9087CAF933AEQ36257068-72080C8A-4D60-46A7-943D-8CC312433493Q36352462-B5E29661-ADF2-4FE8-97CE-4D75D503362DQ36393095-6F96B06F-D90F-4477-8A1C-14184F2A1CADQ36964450-354994FE-3E20-4CF4-B1B8-644D6BAC2EE6Q37177918-0FE4EC19-943F-42C7-8CFE-118513F84E9BQ37225720-B4CC2564-E36B-4338-989E-2BDB0750CD38Q37294977-90836C5C-3A76-473D-B828-4D96C891FB5BQ37312970-729C254D-767D-4B5C-8AB2-4C5F23587765Q37349748-3F980CDF-88F1-4912-BC6B-B13D9EFE272FQ37421431-181D90CD-81D5-4C6E-8292-2A122BDA2E5DQ37496695-40BAAF3B-7311-4F2E-9EE3-C64C9F9387CDQ37636844-C9F6E23A-6AA4-4572-8DE9-20A3D18459A3
P2860
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@ast
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@en
type
label
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@ast
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@en
prefLabel
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@ast
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@en
P2093
P2860
P50
P356
P1476
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
@en
P2093
A J Holmes
C Carnaghi
G Finocchiaro
M Varella-Garcia
P2860
P2888
P356
10.1038/SJ.BJC.6604439
P407
P577
2008-06-24T00:00:00Z